Survodutide Shows Significant Improvement in MASH and Liver Fibrosis in Phase 2 Trial

Patients taking the glucagon/glucagon-like peptide-1 receptor dual agonist survodutide saw an 83% improvement in ...

AUGUST 9, 2024